Vivani Medical (NASDAQ:VANI) Releases Earnings Results, Beats Estimates By $0.01 EPS

Vivani Medical (NASDAQ:VANI) released its earnings results on Thursday. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.10) by $0.01, FiscalAI reports.

Vivani Medical Trading Down 4.4%

Shares of VANI stock opened at $1.08 on Friday. The stock has a market cap of $84.42 million, a PE ratio of -2.40 and a beta of 3.17. Vivani Medical has a 12 month low of $0.91 and a 12 month high of $1.92. The company’s fifty day moving average price is $1.26 and its 200-day moving average price is $1.36.

Insider Buying and Selling at Vivani Medical

In related news, Director Gregg Williams bought 1,575,231 shares of the business’s stock in a transaction dated Sunday, March 15th. The shares were purchased at an average cost of $1.07 per share, with a total value of $1,685,497.17. Following the completion of the purchase, the director owned 31,357,183 shares in the company, valued at approximately $33,552,185.81. The trade was a 5.29% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In the last quarter, insiders purchased 4,664,347 shares of company stock valued at $5,666,549. Corporate insiders own 46.40% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of VANI. Citadel Advisors LLC bought a new stake in shares of Vivani Medical during the 3rd quarter valued at $26,000. Susquehanna International Group LLP raised its position in Vivani Medical by 100.5% in the 3rd quarter. Susquehanna International Group LLP now owns 32,314 shares of the company’s stock worth $46,000 after purchasing an additional 16,200 shares during the period. Jane Street Group LLC bought a new stake in shares of Vivani Medical during the fourth quarter worth $60,000. Renaissance Technologies LLC boosted its holdings in shares of Vivani Medical by 118.4% in the fourth quarter. Renaissance Technologies LLC now owns 97,985 shares of the company’s stock valued at $121,000 after purchasing an additional 53,127 shares during the period. Finally, Marshall Wace LLP bought a new position in Vivani Medical during the 4th quarter worth about $174,000. 6.78% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Vivani Medical in a research note on Friday, January 9th. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $4.00.

Vivani Medical Company Profile

Vivani Medical Solutions, Inc (NASDAQ: VANI) is a medical technology company focused on the design, development and commercialization of advanced specimen retrieval and hemostasis products for minimally invasive diagnostic procedures. Its core mission is to enhance procedural safety and streamline clinical workflows for interventional radiologists and pathology laboratories.

The company’s flagship offerings include the StopBleed Retrieval Device and StopBleed Pad, which integrate proprietary hemostatic materials to control bleeding at biopsy sites and preserve tissue integrity.